Endobios© Biotech: Advancing Therapeutics for Epilepsy

Endobios© is an EU-based startup advancing a potential first-in-class small molecule anticonvulsant, currently in the early preclinical stages of drug development.

X-ray illustration of a human head showing the brain

Epilepsy Awareness

  • A chronic disorder characterized by recurrent seizures driven by uncontrolled, excessive neuronal electrical discharges within the brain.
  • One of the most common neurological disorders: 50 million people worldwide
1 in 3 patients with uncontrolled epilepsy
  • Epilepsy can arise from a multitude of causes. In 60–70% of cases, the underlying neuronal dysregulation is unknown.
  • Can start at any age
  • Can happen at any time

More people live with EPILEPSY than with Autism, Parkinson's, Multiple Sclerosis and Cerebral Palsy COMBINED.

The ENB-002 Anticonvulsant Drug Candidate

ENB-002 development pipeline: discovery, preclinical, clinical

Compound profile

  • New chemical scaffold (molecular weight <300 g/mol)
  • Unpublished fungal-derived compounds
  • Currently synthesizable

Early preclinical results

  • In vivo anticonvulsant activity (mouse model)
  • Preliminary in vivo data: blood–brain barrier permeable
  • Likely a new mechanism of action / first-in-class (its full characterization is our next main task)
  • Secondary capacity against neuropathic pain (nonopioid)
  • To date, in vivo and in vitro safety

Celso Almeida, PhD, CEO

almeida@endobios.com

Partnering

We welcome two-way collaborations to discover and advance early-stage drug candidates.

Research collaboration network

Investors

Contact us to know more about our deck, our team and international scientific advisory board.

Celso Almeida, PhD, CEO

almeida@endobios.com